The CVS GLP-1 study, released by CVS Health on November 15, 2026, found lower medical bills among people using these medicines, but the savings didn't cover the plan's added drug spending. A treatment can help someone's health while still adding to an insurer's total bill.

GLP-1 medicines act on a gut-hormone signal involved in appetite and blood sugar. Semaglutide is one example.

As of November 19, 2026, the day this article was written, CVS Health's November 15 release reports that spending gap. For someone worried about coverage, the finding helps explain the budget argument. It doesn't decide whether treatment is worthwhile for that person.

What the CVS GLP-1 study measured

CVS compared adults with private Aetna insurance who started GLP-1 medicines in 2023–2025 with similar members who didn't use them. The plans were fully insured, meaning the insurer carried the risk of paying claims. Follow-up extended to three years.

Researchers matched people on age, health conditions, earlier health care use and spending. Matching makes groups more comparable; it cannot remove every difference between them.

The November 2026 white paper, GLP-1s: Good Drugs, High Prices, is a report published by CVS. It isn't a peer-reviewed journal article, meaning one checked by outside experts before publication. Each follow-up year used separately matched groups, with fewer eligible people at three years. These aren't three annual snapshots of one unchanged group.

The company's interests matter, too. CVS includes Aetna and CVS Caremark. Caremark is a pharmacy benefit manager, a business that manages prescription benefits and negotiates drug costs. CVS therefore has a financial stake in this price discussion. Independent checks of its findings would be useful.

For a semaglutide prescription, this distinction matters: an insurer's spending comparison answers a different question from a clinician's assessment of medical benefit.

What break-even means for coverage

Net price is the plan's cost after discounts and rebates—money returned after the initial payment. It differs from the manufacturer's list, or sticker, price and the patient's payment.

Break-even means medical savings balance added drug spending. CVS estimated how far net prices would need to fall to reach that balance over three years. Its estimate describes a study population, rather than a patient offer or a universal target.

The paper uses higher-risk diabetes and younger, lower-risk obesity patients as examples of why the arithmetic can differ. It doesn't publish a ranking showing which patient group came closest to break-even.

This helps explain the tension behind plans dropping GLP-1 coverage. A plan can recognize health benefits while still facing a larger budget. Whether that justifies restricting coverage is a separate policy decision.

A headline about this model also cannot settle an individual benefits question. The relevant documents remain the exact plan's covered-drug list and conditions. The open enrollment coverage guide covers that check; the GLP-1 insurance denial study addresses a different part of access.

Staying on treatment was linked to larger savings

CVS defined consistent use as filled prescriptions covering at least 80% of follow-up days. Fills show that medicine was available, not that every dose was used.

Consistent users had larger medical savings, but their added drug spending also rose. Their overall spending gap was larger. Those findings don't establish that consistent use caused the differences: people able to continue may differ in other ways.

Affordability is part of that conversation. The separate cost and adherence study examines patient spending and refill patterns. Adherence means how consistently treatment is used. A plan's net spending and a household's recurring bill can put pressure on different parts of the same treatment relationship.

Neither result is a reason to stretch doses or switch medicines to improve an insurer's arithmetic. Semaglutide and tirzepatide need their own clinical assessment. A budget comparison cannot choose between them for an individual.

What the finding does not mean

Financial break-even is a narrow test. Cost-effectiveness asks a broader question: are the health gains worth the added spending? A medicine can add costs and still provide benefits people value.

A 2025 JAMA Health Forum analysis by Hwang and colleagues modeled lifetime outcomes for semaglutide and tirzepatide. It projected health gains but did not find either cost-effective at the net prices assumed then. Those historical assumptions are not today's quote, and a lifetime projection is not observed lifetime follow-up.

There is also trial evidence that looks directly at health. In SELECT, published in the New England Journal of Medicine in 2023, 17,604 adults had existing heart or blood vessel disease and overweight or obesity, without diabetes. Heart-related death, nonfatal heart attack or nonfatal stroke occurred in 6.5% receiving semaglutide and 8.0% receiving placebo, a comparison treatment without the drug.

That result belongs to that population and studied product. It does not measure an insurer's savings or predict one person's outcome. Adverse events, meaning health problems reported during the trial, led 16.6% receiving semaglutide to stop the trial product permanently, versus 8.2% receiving placebo. Benefit and tolerability both belong in the medical decision.

A three-year spending window also leaves later events outside the count. Any later costs from heart events or joint replacements would need longer follow-up. That limitation doesn't establish that eventual savings will close the gap.

Compounded preparations are a separate question, too. Compounding means preparing medication for an individual prescription.

As of November 19, 2026, the day this article was written, the U.S. Food and Drug Administration (FDA) explains that it does not review compounded drugs before marketing. That includes review of safety, effectiveness and quality.

Semaglutide and tirzepatide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications, which are different from an FDA-approved product: the formulations offered here are not FDA-approved.

A licensed provider may still prescribe — that decision is between you and your doctor.

What to watch next

The useful next steps in the evidence are independent review, fuller reporting of patient groups and longer follow-up. Changes in negotiated drug spending would also require a fresh calculation. An estimate built around one population and period cannot settle every future coverage decision.

For someone already prescribed treatment, the near-term questions are more personal: what benefit is being tracked, what side effects have appeared, and can treatment continue under the plan's terms? Those questions belong together. Medical value, the plan's budget and the patient's bill each need their own answer.

At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies.